UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 356

Sortiert nach

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy

Clinical radiology, 2014-08, Vol.69 (8), p.841-848

2014

Link zum Volltext

Verfügbarkeit prüfen

An Assessment of Jejunostomy Tube Placement in Patients Undergoing Pancreaticoduodenectomy for Adenocarcinoma: Routine Placement is not Justified

The Journal of surgical research, 2014-02, Vol.186 (2), p.502-502

2014

Link zum Volltext

Verfügbarkeit prüfen

Factors Associated With Survival in Patients With Oligometastatic Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S202-S202

2013

Link zum Volltext

Verfügbarkeit prüfen

Cancer Research and Clinical Oncology for the Next Decade

Annals of oncology, 2012-10, Vol.23, p.xi9

Johnson, B.E.

2012

Link zum Volltext

Verfügbarkeit prüfen

Sarcopenia Predicts Operative Complications Following Pancreatectomy for Adenocarcinoma

The Journal of surgical research, 2014-02, Vol.186 (2), p.502-502

2014

Link zum Volltext

Verfügbarkeit prüfen

9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC)

European journal of cancer (1990), 2011, Vol.47, p.S597-S597

2011

Link zum Volltext

Verfügbarkeit prüfen

NAUTIKA1: A Multicenter Phase II Study with a PD-L1+ Cohort of Patients Receiving Atezolizumab (Atezo) with Low-Dose Stereotactic Body Radiation Therapy (SBRT) as Neoadjuvant Therapy for Resectable Stage IB-III NSCLC

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.e392-e393

2022

Link zum Volltext

Verfügbarkeit prüfen

P1.25-16 Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S275-S276

2023

Link zum Volltext

Verfügbarkeit prüfen

145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S90-S91

2023

Link zum Volltext

Verfügbarkeit prüfen

P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S323-S324

2023

Link zum Volltext

Verfügbarkeit prüfen

P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S297-S298

2023

Link zum Volltext

Verfügbarkeit prüfen

P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S313

2023

Link zum Volltext

Verfügbarkeit prüfen

MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S175

2023

Link zum Volltext

Verfügbarkeit prüfen

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC

Annals of oncology, 2021-12, Vol.32, p.S1373

2021

Link zum Volltext

Verfügbarkeit prüfen

EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S233-S234

2022

Link zum Volltext

Verfügbarkeit prüfen

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

Annals of oncology, 2022-08, Vol.33 (8), p.836-844

2022

Link zum Volltext

Verfügbarkeit prüfen

PD01.05 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1136-S1136

2019

Link zum Volltext

Verfügbarkeit prüfen

OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S38-S39

2022

Link zum Volltext

Verfügbarkeit prüfen

CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC

Annals of oncology, 2019-11, Vol.30, p.ix179

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer

Annals of oncology, 2014-02, Vol.25 (2), p.409-415

2014

Link zum Volltext

Verfügbarkeit prüfen

The oxidation of copper catalysts during ethylene epoxidation

Physical chemistry chemical physics : PCCP, 2015-01, Vol.17 (38), p.25073-25089

2015

Link zum Volltext

Verfügbarkeit prüfen

Neighborhood covenants and restrictions: an examination of fit

GeoJournal, 2013-08, Vol.78 (4), p.601-614

Johnson, Brian Edward

2013

Link zum Volltext

Verfügbarkeit prüfen

B09 The CANOPY Program: Three Phase 3 Studies Evaluating Canakinumab in Patients with Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.S30-S30

2020

Link zum Volltext

Verfügbarkeit prüfen

Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis

British journal of dermatology (1951), 1993-01, Vol.128 (1), p.49-56

1993

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 356

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(310)
Mit Volltextzugriff
(325)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(354)
Japanisch
(32)
Spanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(211)
Life Sciences & Biomedicine
(163)
Biological And Medical Sciences
(100)
Fundamental And Applied Biological Sciences. Psychology
(74)
Humans
(63)
Animals
(52)
Female
(52)
Male
(41)
Physical Sciences
(38)
Technology
(32)
Physics
(31)
Agriculture
(29)
Phytopathology. Animal Pests. Plant And Forest Protection
(29)
Control
(26)
Entomology
(26)
Medical Sciences
(26)
Adult
(25)
Protozoa. Invertebrates
(25)
Dermatology
(24)
Middle Aged
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy

An Assessment of Jejunostomy Tube Placement in Patients Undergoing Pancreaticoduodenectomy for Adenocarcinoma: Routine Placement is not Justified

Factors Associated With Survival in Patients With Oligometastatic Non-Small Cell Lung Cancer (NSCLC)

Cancer Research and Clinical Oncology for the Next Decade

Sarcopenia Predicts Operative Complications Following Pancreatectomy for Adenocarcinoma

9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC)

NAUTIKA1: A Multicenter Phase II Study with a PD-L1+ Cohort of Patients Receiving Atezolizumab (Atezo) with Low-Dose Stereotactic Body Radiation Therapy (SBRT) as Neoadjuvant Therapy for Resectable Stage IB-III NSCLC

P1.25-16 Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study

145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study

P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer

P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC

P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1

MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC

EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

PD01.05 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients

OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing

CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer

The oxidation of copper catalysts during ethylene epoxidation

Neighborhood covenants and restrictions: an examination of fit

B09 The CANOPY Program: Three Phase 3 Studies Evaluating Canakinumab in Patients with Non-Small Cell Lung Cancer (NSCLC)

Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis

Suchergebnisse filtern